Phathom Pharmaceuticals
PHAT
40 hedge funds and large institutions have $677M invested in Phathom Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 40 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
88.91% more ownership
Funds ownership: 0% → 88.91% (+89%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$183M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$91.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$52.8M |
| 4 |
Janus Henderson Group
London,
|
+$36.9M |
| 5 |
A
Abingworth
London,
United Kingdom
|
+$30.2M |
Top Sellers
PHAT Hedge Fund Activity: Q4 2019 in Review
40 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q4 2019, worth a combined $677M.
Buyers outnumbered sellers: 40 funds opened new PHAT positions and 0 closed out — a net gain of 40 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Frazier Management, opening a new position worth an estimated $183M.
- 40 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $677M of Phathom Pharmaceuticals stock for Q4 2019.
- 40 funds opened new Phathom Pharmaceuticals positions in Q4 2019 and 0 closed out, a net change of +40 holders.
- The largest Phathom Pharmaceuticals buyer in Q4 2019 was Frazier Management, an estimated $183M added.
Based on aggregated 13F filings for Q4 2019.